Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | FECH | P22830 | 1/20 | 0.73 |
| ▸ | MST1R | Q04912 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400059 | 0.90 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL398297 | 0.90 | MET (0.86) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400225 | 0.89 | MET (0.80) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL401276 | 0.88 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400072 | 0.88 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399288 | 0.88 | MET (0.84) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399926 | 0.88 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399928 | 0.88 | MET (0.87) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL401837 | 0.88 | MET (0.82) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400639 | 0.87 | MET (0.85) | METCYP3A4CYP2D6CYP2C9FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | claimed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | claimed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | claimed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | claimed |
| EP-2049494-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | claimed |
| WO-2008008310-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012076-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | MET 3/4885CYP3A4 3774/4885CYP2D6 3284/4885 |
| US-20090203684-A1 | Tyrosine kinase inhibitors | ABL1, MET, ERBB2 | MET 2/4885CYP3A4 3658/4885CYP2D6 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.